9 results on '"William C, Gruber"'
Search Results
2. A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age
- Author
-
Himal Lal, Sarah Mirza, James Peterson, Brandon Essink, Daniel A. Scott, William C. Gruber, Kathrin U. Jansen, Xia Xu, Kari Yacisin, Wendy Watson, and Ingrid L. Scully
- Subjects
Pneumococcal disease ,030231 tropical medicine ,Immunology ,medicine.disease_cause ,complex mixtures ,Pneumococcal Infections ,Pneumococcal conjugate vaccine ,Pneumococcal Vaccines ,03 medical and health sciences ,Immunogenicity, Vaccine ,0302 clinical medicine ,Double-Blind Method ,Streptococcus pneumoniae ,medicine ,Humans ,Immunology and Allergy ,030212 general & internal medicine ,Aged ,Pharmacology ,Vaccines, Conjugate ,business.industry ,Immunogenicity ,food and beverages ,Antibodies, Bacterial ,Clinical trial ,pneumococcal conjugate vaccine ,business ,Research Article ,Research Paper ,medicine.drug ,Conjugate - Abstract
Pneumococcal disease can be serious and debilitating in older adults. Pneumococcal conjugate vaccines (PCVs), such as the 13-valent PCV (PCV13), reduce pneumococcal disease rates caused by vaccine serotypes. Development of PCVs offering additional coverage against serotypes not contained in PCV13 can reduce disease burden further. The complementary 7-valent PCV (cPCV7) contains seven non-PCV13 serotypes (8, 10A, 11A, 12F, 15B, 22F, 33F) and can expand coverage by supplementing direct or indirect protection from existing PCVs. This phase 1/2, randomized, active-controlled, observer-blinded study evaluated cPCV7 safety and immunogenicity in healthy adults 50–85 years of age. Stage 1 randomized 66 healthy adults (50–64 years) naive to pneumococcal vaccines to receive cPCV7 or licensed tetanus, diphtheria, and acellular pertussis vaccine; Stage 2 randomized 445 healthy adults (65–85 years) previously vaccinated with PCV13 to receive cPCV7 or 23-valent polysaccharide vaccine. Local reactions and systemic events up to 14 days and adverse events (AEs) through 1 month after vaccination were assessed. Immunogenicity was evaluated by serotype-specific opsonophagocytic activity (OPA) assays before and 1 month after vaccination (and after 12 months in Stage 2). Rates of local reactions, systemic events, and AEs were generally similar after receipt of cPCV7 or control. Robust OPA responses were observed for all seven serotypes 1 month after cPCV7; titers declined yet remained above baseline 12 months after vaccination. Overall, this study found that in adults ≥50 years of age, cPCV7 was safe, well tolerated, and elicited functional immune responses to vaccine serotypes. ClinicalTrials.gov: NCT03313050
- Published
- 2021
3. A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States
- Author
-
Wendy Watson, Ingrid L. Scully, William C. Gruber, Daniel A. Scott, Kathrin U. Jansen, Gary Baugher, David R. FitzPatrick, Yahong Peng, and Mariano Young
- Subjects
safety ,Adult ,Serotype ,030231 tropical medicine ,Immunology ,cPCV7 ,immunogenicity ,Serogroup ,medicine.disease_cause ,Pneumococcal Infections ,Pneumococcal conjugate vaccine ,Pneumococcal Vaccines ,03 medical and health sciences ,0302 clinical medicine ,Japan ,Streptococcus pneumoniae ,medicine ,Humans ,Immunology and Allergy ,030212 general & internal medicine ,Disease burden ,Pharmacology ,Vaccines, Conjugate ,business.industry ,Immunogenicity ,clinical trial ,PCV20 ,Antibodies, Bacterial ,Virology ,United States ,pneumococcal conjugate vaccine ,Child, Preschool ,business ,Research Article ,Research Paper ,medicine.drug ,Conjugate - Abstract
Expanding serotype coverage of pneumococcal conjugate vaccines (PCVs) to target prevailing disease-causing serotypes could further reduce disease burden. To address this need, 2 different PCVs have been investigated: a 20-valent PCV (PCV20; includes the 13 serotypes in the 13-valent PCV [PCV13] plus 7 additional serotypes [8, 10A, 11A, 12F, 15B, 22F, 33F]) and a complementary 7-valent PCV (cPCV7; contains only the 7 additional serotypes). This phase 1b, randomized, controlled, double-blind study evaluated PCV20 and cPCV7 safety and immunogenicity in healthy Japanese adults 18–49 years of age residing in the United States for ≤5 years. Participants (n = 104) were randomized equally to receive a single dose of PCV20, cPCV7, or PCV13. Immunogenicity was assessed at baseline and 1 month after vaccination using serotype-specific opsonophagocytic activity (OPA) titers and serotype-specific immunoglobulin G (IgG) concentrations. Prompted local reactions and systemic events; adverse events (AEs); and serious AEs and newly diagnosed chronic disease were assessed 14 days, through 1 month, and upto 6 months following vaccination, respectively. OPA immune responses were robust for all 20 serotypes in the PCV20 group and for the 7 serotypes in the cPCV7 group 1 month after vaccination. IgG immune response showed similar trends. Injection site pain and muscle pain were the most common local reaction and systemic event; the majority were mild or moderate in severity. Few AEs and no severe AEs, serious AEs, or safety-related withdrawals were reported. Taken together, administration of PCV20 or cPCV7 in Japanese adults was well tolerated and induced robust serotype-specific functional immune responses. NCT03642847.
- Published
- 2021
4. Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
- Author
-
William C. Gruber, Vani Sundaraiyer, Beate Schmoele-Thoma, Alejandra Gurtman, Martin van Cleeff, Daniel A. Scott, Thomas R. Jones, and Richard N. Greenberg
- Subjects
Male ,Time Factors ,13-valent pneumococcal conjugate vaccine ,030231 tropical medicine ,Immunology ,Immunization, Secondary ,opsonophagocytic activity ,Serogroup ,complex mixtures ,Pneumococcal Infections ,Pneumococcal conjugate vaccine ,Persistence (computer science) ,Pneumococcal Vaccines ,03 medical and health sciences ,0302 clinical medicine ,Double-Blind Method ,Phagocytosis ,stomatognathic system ,adults ,otorhinolaryngologic diseases ,medicine ,Humans ,Immunology and Allergy ,clinical studies ,030212 general & internal medicine ,Aged ,Pharmacology ,biology ,business.industry ,Vaccination ,Middle Aged ,Opsonin Proteins ,Antibodies, Bacterial ,Pneumococcal polysaccharide vaccine ,Virology ,3. Good health ,Streptococcus pneumoniae ,biology.protein ,Female ,Antibody persistence ,Antibody ,business ,Research Paper ,medicine.drug - Abstract
Vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) followed ≥ 1 year by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for immunocompetent adults ≥ 65 years of age in the United States. This study assessed antipneumococcal opsonophagocytic activity (OPA) geometric mean titers (GMTs) to PCV13 in PPSV23-naive and PPSV23-preimmunized adults 1 year after a second vaccine dose. Two parent studies were conducted previously: (1) PPSV23 vaccine–naive subjects (60–64 years of age at enrollment) received PCV13 followed by PCV13 or PPSV23 1 year later or PPSV23 followed by PCV13 1 year later; and (2) subjects (≥ 70 years of age at enrollment) vaccinated with PPSV23 ≥ 5 years before study entry received PCV13 or PPSV23 followed by PCV13 1 year later. Overall, 962 subjects (PPSV23-naive, n = 519; PPSV23-preimmunized, n = 443) who received both vaccinations in the parent studies were enrolled. Numerically higher OPA GMTs persisted for at least 1 year after administration of PCV13 as the initial vaccine (PCV13/PPSV23 or PCV13/PCV13) compared with those who received PPSV23 either 1 or 5 years prior (PPSV23/PCV13). This impairment in antibody responses to subsequent PCV13 vaccination produced by initial PPSV23 vaccination persisted for at least 1 year. OPA GMTs were numerically higher for most serotypes 1 year after 2 doses of PCV13 compared with 1 year after the first PCV13 dose. These data suggest PCV13 should be given first if both vaccines are to be administered, higher immune responses were achieved when PCV13 was given first and persisted at least 1 year (ClinicalTrials.gov Identifier: NCT01025336).
- Published
- 2019
5. Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial
- Author
-
Keri Clarke, Kathrin U. Jansen, Beate Schmoele-Thoma, Daniel A. Scott, Vani Sundaraiyer, Scott Patterson, Shite Sebastian, Nicola P. Klein, H. Jackson Downey, Allison Thompson, Wendy Watson, and William C. Gruber
- Subjects
Male ,Quadrivalent Inactivated Influenza Vaccine ,Prevnar 13 ,PPSV23 ,030231 tropical medicine ,Immunology ,quadrivalent inactivated influenza vaccine ,Pneumococcal Infections ,Pneumococcal conjugate vaccine ,law.invention ,Pneumococcal Vaccines ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Double-Blind Method ,Randomized controlled trial ,law ,Influenza, Human ,adults ,Humans ,Immunology and Allergy ,Medicine ,030212 general & internal medicine ,Aged ,Pharmacology ,Vaccines, Conjugate ,business.industry ,Vaccination ,coadministration ,Hemagglutination Inhibition Tests ,Middle Aged ,Antibodies, Bacterial ,Virology ,Streptococcus pneumoniae ,Pneumococcal vaccine ,Influenza Vaccines ,Immunoglobulin G ,Female ,business ,Research Paper ,Conjugate ,medicine.drug - Abstract
Immune responses to 13-valent pneumococcal conjugate vaccine (PCV13) and quadrivalent inactivated influenza vaccine (QIV) in older adults may vary with coadministration and previous pneumococcal polysaccharide vaccination. This study assessed safety and noninferiority of immune responses to coadministered PCV13 and QIV compared with each vaccine given alone. Adults ≥50 years old preimmunized with ≥1 dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) ≥1 year before enrollment were randomized 1:1 to receive PCV13+QIV then placebo 1 month later or placebo+QIV then PCV13 1 month later. Administration of PCV13 and placebo was blinded; QIV was administered open-label. Pneumococcal serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) 1 month after PCV13, and influenza hemagglutination inhibition assay GMTs 1 month after QIV were measured. Prespecified noninferiority was demonstrated by a lower bound of the 2-sided 95% CI for geometric mean ratios >0.5. Safety endpoints included proportions of subjects with adverse and serious adverse events. Of 882 randomized subjects, 846 comprised the evaluable immunogenicity population. Immune responses to all 13 pneumococcal serotypes and all 4 influenza strains 1 month after PCV13+QIV were noninferior to responses 1 month after each vaccine given alone. No safety concerns were identified. Immune responses to coadministered PCV13 and QIV were noninferior to responses after each vaccine given alone, although generally lower for coadministered PCV13. PCV13 and QIV can be administered concomitantly to adults ≥50 years of age preimmunized with PPSV23.
- Published
- 2018
6. Safety, tolerability, and immunogenicity of a novel 4-antigen Staphylococcus aureus vaccine (SA4Ag) in healthy Japanese adults
- Author
-
Joseph Eiden, Alejandra Gurtman, Takuma Yonemura, David A. Cooper, Kathrin U. Jansen, Megumi Inoue, William C. Gruber, Yasuko Shoji, Annaliesa S. Anderson, Masakazu Aizawa, and James Baber
- Subjects
0301 basic medicine ,Serotype ,Staphylococcus aureus ,030106 microbiology ,Immunology ,medicine.disease_cause ,law.invention ,Microbiology ,03 medical and health sciences ,0302 clinical medicine ,Antigen ,law ,vaccine ,manganese transporter C ,Immunology and Allergy ,Medicine ,030212 general & internal medicine ,Pharmacology ,business.industry ,Immunogenicity ,functional antibodies ,Safety tolerability ,capsular polysaccharide ,Clumping factor A ,Recombinant DNA ,sense organs ,business ,clumping factor A ,Research Paper - Abstract
A novel Staphylococcus aureus 4-antigen vaccine (SA4Ag) is under development, comprising capsular polysaccharide serotypes 5 and 8 (CP5 and CP8) conjugated to CRM197, recombinant protein clumping factor A (rmClfA), and recombinant manganese transporter protein C (MntC). We evaluated SA4Ag safety, tolerability, and immunogenicity in Japanese adults aged 20 to 64 and 65 to 85 years. A total of 136 healthy Japanese adults (68 per age group) were randomized 1:1 to receive single-dose SA4Ag or placebo intramuscularly (Day 1). Safety assessments included reactogenicity and adverse events. The ability of the vaccine to induce immune responses that are considered functional due to their ability to facilitate the killing of S. aureus or neutralize S. aureus virulence mechanisms was assessed using 5 different antigen-specific assays. SA4Ag was well tolerated in both age groups, with no safety concerns. At Day 29, > 85% of SA4Ag recipients in each age group achieved predefined thresholds for each antigen. Antibody geometric mean-fold rises from baseline to Day 29 in SA4Ag groups were: > 80 and > 30 for CP5 and CP8 (opsonophagocytic activity assay), > 10 for ClfA (fibrinogen-binding inhibition assay), and > 15 and > 7 for ClfA and MntC (competitive Luminex® immunoassay), respectively. Antibody titers decreased through Month 12 but remained well above baseline and placebo levels. SA4Ag had an acceptable safety profile and induced rapid and robust functional immune responses in both age groups. These results support ongoing development of SA4Ag for the prevention of invasive S. aureus disease in elective-surgery patients in Japan, North America, and Europe.
- Published
- 2018
7. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial
- Author
-
Pravin Dinkar Supe, Mark Cutler, Bhagirath B. Solanki, Vani Sundaraiyer, Christine Juergens, Daniel A. Scott, Beate Schmoele-Thoma, Manojkumar B. Chopada, Natacha Le Dren-Narayanin, and William C. Gruber
- Subjects
Male ,medicine.medical_specialty ,Pediatrics ,030231 tropical medicine ,Immunology ,Immunization, Secondary ,India ,medicine.disease_cause ,Pneumococcal conjugate vaccine ,Pneumococcal Vaccines ,03 medical and health sciences ,Immunogenicity, Vaccine ,0302 clinical medicine ,Double-Blind Method ,Streptococcus pneumoniae ,Humans ,Immunology and Allergy ,Medicine ,030212 general & internal medicine ,Aged ,Pharmacology ,Vaccines, Conjugate ,business.industry ,Immunogenicity ,Public health ,Vaccination ,Middle Aged ,Pneumonia, Pneumococcal ,Antibodies, Bacterial ,Research Papers ,Immunoglobulin G ,Life expectancy ,Female ,Open label ,business ,Immunologic Memory ,Immunologic memory ,medicine.drug - Abstract
Streptococcus pneumoniae infection is a major global public health concern in older adults, especially as life expectancy continues to increase in most countries, including India. Recently, a 13-valent pneumococcal conjugate vaccine (PCV13) with the ability to enhance immunity (immunologic memory) on natural exposure or revaccination has been shown to protect against community-acquired pneumonia and invasive pneumococcal disease in adults 65 years of age and older. An unconjugated 23-valent pneumococcal polysaccharide vaccine has been available for decades; however, data on protection against pneumonia are inconsistent. For the first time, a multicenter study has been conducted in India to assess the safety and immunogenicity of a single dose of PCV13 in adults aged 50 to 65 years. In this study, PCV13 elicited robust immune responses against all 13 pneumococcal serotypes as reflected by the magnitude of geometric mean fold rises (range, 6.6-102.7) in functional antibody levels from before to 1 month after vaccination. No serious adverse events occurred. These clinical trial findings support the safety and immunogenicity of PCV13 when administered to adults in India and indicate that a single dose of PCV13 has the potential to protect against vaccine-type pneumococcal disease in adults aged 50 to 65 years. ClinicalTrials.gov identifier: NCT02034877.
- Published
- 2017
8. IMMUNIZATION IN HEMATOPOIETIC CELL TRANSPLANTATION
- Author
-
Kathryn M. Edwards, William C. Gruber
- Subjects
Pediatrics, Perinatology and Child Health ,Pathology and Forensic Medicine - Published
- 2000
9. IMMUNIZATION IN HEMATOPOIETIC CELL TRANSPLANTATION
- Author
-
M. Edwards, William C. Gruber, Kathryn, primary
- Published
- 2000
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.